Search

Relutrigine

Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine). … Relutrigine is a small molecule drug. The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator.

Delorazepam

In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.

OSI-930

OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. … In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers

Quavonlimab

Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

Camptothecin

Camptothecin is an alkaloid isolated from the stem wood of the Chinese tree, <i>Camptotheca acuminata</i>. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I.

Pantethine

It consists of two molecules of pantetheine that form a dimer via disufide linkages, and acts as an intermediate in the production of Coenzyme A. … Pantethine is available as a dietary supplement for lowering blood cholesterol and triglycerides.

Carboxin

A systemic agricultural fungicide and seed treatment agent.

Pinacidil

The above processes result in reduced blood pressure. This drug has been discontinued by the FDA. … Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance.

Bordetella pertussis pertactin antigen (formaldehyde inactivated)

BMS-564929

So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).